Furthermore, PTL was proven to inhibit the tumor promoter-induced NF-κB activity and modulate p21 and cyclin D1 NF-κB target genes, and also inhibit the TPA-induced tumor growth in vivo. Here, CCND1 is linked to neoplasm.